Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy
Open Access
- 20 October 2025
- journal article
- case report
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-5
Abstract
Ciltacabtagene-autoleucel (cilta-cel) is a CAR-T cell therapy highly active in relapsed/refractory multiple myeloma but can induce severe immune-mediated toxicities. We describe two patients who developed chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel. Patient 1 presented with rapidly progressive gait ataxia, flaccid paraparesis, and oculomotor palsy 112 days post infusion; Patient 2 developed an analogous syndrome on day 19. In both patients, electromyography and nerve-conduction studies confirmed sensorimotor axonal-demyelinating neuropathy; brain MRI and CSF infection panels were unremarkable. CAR-T cells were detectable in blood and CSF, yet a predominance of CD8⁺ non-CAR-Tcells was observed. TCR-β sequencing revealed a hyper-expanded clone (~30% of all reads) in patient 1 versus a polyclonal repertoire in patient 2. High-dose dexamethasone plus intravenous immunoglobulin failed to improve neurologic symptoms and prompted T-cell-depleting cyclophosphamide, which lowered CAR- and non-CAR-T cells. Patient 1 died from respiratory failure, whereas patient 2 improved and could be discharged. These observations indicate that CIDP is a severe complication of cilta-cel therapy and may arise from bystander expansion of autoreactive CD8⁺ T-cells rather than direct CAR-T cell activity. Timely escalation to T-cell-depleting therapy may improve outcomes.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (HA 8790/3-1, KR 3886/7-1, HA 8790/3-1, KR 3886/7-1)
This publication has 14 references indexed in Scilit:
- Immunotherapy-related cognitive impairment after CAR T cell therapy in miceCell, 2025
- Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeThe Lancet Oncology, 2025
- Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS DataTransplantation and Cellular Therapy, 2024
- Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myelomaBlood Cancer Journal, 2024
- Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma PatientsClinical Cancer Research, 2024
- Chimeric antigen receptor T cell therapy for autoimmune diseaseNature Reviews Immunology, 2024
- BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathyhLife, 2024
- Autoreactive T cells target peripheral nerves in Guillain–Barré syndromeNature, 2024
- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studiesBlood Cancer Journal, 2022
- Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapyNature Medicine, 2021